Abstract
Backgrounds. TSP-1 is a glycoprotein that functions in the biology of bladder cancer. We investigated the relationship between the distribution of TSP-1-1223 A/G polymorphism (rs2169830) and the clinical characteristics of bladder cancer. Materials and Methods. TaqMan assay was performed to determine the genotype of 609 cases and 670 control subjects in a Chinese population. Logistic regression was used to assess the association between the polymorphism and the risk of bladder cancer. Quantitative real-time polymerase chain reaction was performed to determine TSP-1 mRNA expression. Survival curves were generated using the Kaplan-Meier method. Results. No significant differences were detected in the genotype frequencies of healthy control subjects and patients with bladder cancer. By contrast, the time until the first recurrence differed significantly between genotypes (P = 0.017). The expression of TSP-1 mRNA in bladder cancer tissues was lower in patients with an AG genotype than in those with an AA genotype. The lowest expression was observed in patients with a GG genotype. Conclusions. In conclusion, TSP-1-1223 A/G polymorphism may contribute to the recurrence of bladder cancer in Chinese population.
Highlights
Bladder cancer is the second most common genitourinary malignancy and the sixth most common cancer in the world [1]
The frequency of the first-degree relatives with cancer was higher in the cases than in the control subjects (27.8% versus 7.2%; P < 0.001). These variables were further adjusted in the multivariate logistic regression analysis to assess the main effect of the TSP-1-1223 A/G polymorphism on bladder cancer risk
We further investigated whether or not TSP-1-1223 A/G polymorphism is associated with the recurrence of bladder cancer
Summary
Bladder cancer is the second most common genitourinary malignancy and the sixth most common cancer in the world [1]. The incidence of bladder cancer increases with age, and the peak is reached approximately at the age of 60 years; bladder cancer is three times more common in men than in women [3]. Among the newly diagnosed cases of transitional cell carcinomas, approximately 75% to 80% of these cases present superficial tumours; 50% to 70% of these superficial tumours relapse within five years; and roughly 10% to 20% progress to a more aggressive disease [4]. Bladder cancer is a multifactorial disease mediated by genetic abnormalities, environmental factors, and chronic irritation [5]. Many individuals are exposed to these risk factors, only a fraction of exposed individuals develop bladder cancer in their lifetime, suggesting that genetic variations may participate in bladder carcinogenesis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
